Status:
TERMINATED
Erythropoietin Role in Acute Kidney Injury
Lead Sponsor:
Saint-Joseph University
Conditions:
Anemia Renal
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The use of erythropoietin to treat anemia in acute kidney injury (AKI) is controversial. No previous clinical trial has assessed the possible reduction of transfusions when erythropoietin is started v...
Detailed Description
Introduction Background and rationale Since the release of the recombinant human erythropoietin (rhuEPO) at the beginning of the 90s, transfusions are less needed to treat anemia in chronic kidney d...
Eligibility Criteria
Inclusion
- All adult patients \> 18 years old hospitalized with acute kidney injury and anemia
Exclusion
- pregnant women, terminally ill patients, patients with major or minor thalassemia, patients with stable chronic kidney disease or patients on dialysis and patients who were receiving rHuEPO or any erythropoiesis-stimulating agent (ESA) before admission.
Key Trial Info
Start Date :
April 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 25 2021
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT03401710
Start Date
April 16 2018
End Date
August 25 2021
Last Update
December 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Georges Hospital
Ajaltoun, Ajaltoun, Lebanon